Skip to content
Helping patients reclaim a life of possibility
Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month 2025
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
Solène Clavreul Head of Medical Education and Scientific Engagement at Myeloma Patients Europe MPE

SOLÈNE CLAVREUL

Solène is Head of Medical Education and Scientific Engagement. She joined the team in January 2021.

Solène holds a PhD in Neuroscience and a Master of Biology and Physiology from Sorbonne University (Paris). She studied brain development during her PhD and then worked on brain cellular diversity as a researcher at the Helmholtz Zentrum München (Germany). Early involved in education, she has been leading holiday camps for children for many years and worked in a science museum during her studies to promote science, design exhibitions and lead workshops.

Interested in science policy and particularly in the health field, she trained herself in European policy implementation, clinical data management and industrial pharma management before joining MPE.
Solène comes from France and currently lives and works in Munich, Germany. She speaks French, English and German.

Recent Posts

Watch our Webinar on myeloma and infections

September 16, 2025

We held our latest webinar on September 11th, called Myeloma and infection: clinical and lived perspectives for myeloma patients, carers and advocates. Jackie Quinn, Myeloma Clinical Nurse Specialist, Belfast Trust presented…

Read more

Shape your myeloma care: New MPE research highlights the power of shared decision-making in myeloma care

September 2, 2025

Myeloma is a form of blood cancer. At diagnosis, and at each relapse, myeloma patients are confronted with complex treatment and care decisions that may feel overwhelming. What are my…

Read more

Myeloma and infection: clinical and lived perspectives webinar

July 30, 2025

Myeloma Patients Europe (MPE) will host a webinar on “Myeloma and infection: clinical and lived perspectives” on Thursday, 11th September 2025 from 17:00 – 18:00 CEST. Aimed at myeloma patients, carers…

Read more

The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patients

July 25, 2025

The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction (i.e., initial) treatment of newly diagnosed myeloma patients (NDMM) who are…

Read more

The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patients

July 25, 2025

Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of…

Read more

European Commission approves first treatment for high-risk smouldering myeloma

July 24, 2025

The European Commission (EC) has approved a new indication for daratumumab (Darzalex®) for the treatment of adult patients with smouldering myeloma (SMM) at high-risk of developing myeloma. This follows a…

Read more
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2025
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About Myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month 2025
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.